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Fortunately, as result of greater awareness, avoidance of
dehydration, smaller catheters, and less nephrotoxic
contrast, rates of contrast-induced acute kidney injury (CI-
AKI) after coronary angiography and percutaneous coro-
nary intervention are decreasing (1). Additionally, there
have been enough published data to form the foundation
for the ﬁrst set of AKI guidelines by the Kidney Disease
Improving Global Outcomes Group, of which, a portion is
dedicated to CI-AKI (2). These guidelines mention the use
of N-acetylcysteine (NAC) but not ascorbic acid as
a possible preventive approach. This having been said, it is
possible to miss a treatment effect that actually exists from
small randomized, controlled trials (RCTs). In this issue of
the Journal, Sadat et al. (3) summarize the RCTs using
short-term ascorbic acid (vitamin C) treatment in the
prevention of CI-AKI in a formal meta-analysis.
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Ascorbic acid or vitamin C is an essential micronutrient
naturally occurring in the human diet that has been studied
for decades in the prevention and treatment of the common
cold, neurodegenerative diseases, malignancies, preeclampsia,
atherosclerosis, and anemia. In virtually every application,
with the exception of the treatment of macular degeneration
(in combination with beta-carotene and vitamin E) and
anemia, ascorbic acid has failed to have a treatment effect when
evaluated with the best sources of evidence (4–10). When
given in high doses to animals, ascorbic acid appears to ame-
lioriate acute ischemic AKI, which probably plays an initial
and minor role in CI-AKI (11). Other basic science studies
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NO is crucial for maintaining perfusion and oxygen supply
in the renalmedulla (13). Reduced production ofNOhas been
implicated in CI-AKI. Additionally, malondialdehyde, an
oxidative stress marker, is inversely related to renal production
of NO. Thus, ascorbic acid may promisingly augment NO
supply and mitigate the oxidative stress and tissue lipid
peroxidation in the renal tubules and peritubular capillary
network that occur with CI-AKI (14). Finally, ascorbic acid
in doses of at least 500 mg orally does have a hemodynamic
effect and results in lowering systemic blood pressure in
humans (15). Of interest, vitamin C does not seem to inﬂu-
ence measures of urine acidity in the majority of studies
published. For example, 2 g of intravenous ascorbic acid
(equivalent to the dose range applied in most of the studies
in this meta-analysis) does not decrease urine pH at 2 h;
conversely, urine pH goes up after administration (16).
In the presentmeta-analysis by Sadat et al. (3), ascorbic acid
was given before and after contrast exposure in 9 RCTs
(6 orally and 3 intravenously) in 1,536 patients, and the overall
pooled treatment effect was a 33% reduction in CI-AKI
(p ¼ 0.034) using a random-effects model. The data
appeared to be both internally and externally consistent
without an impact of publication bias or temporal treatment
bias. There was no formal assessment of safety, but the indi-
vidual trials demonstrated that the therapy was generally safe
and well tolerated. Other studies have shown only rare cases of
renal oxalosis with intravenous vitamin C (17). However, as
the authors point out, a relatively small study (n ¼ 250
subjects) with a neutral or negative result for vitamin C would
overturn the results of this meta-analysis in the future. Thus,
this paper has helped the ﬁeld advance and appropriately
framed ascorbic acid, perhaps in the higher doses and possibly
for a longer duration of time, as a potential therapy to be
tested in large-scale clinical trials. Such a large trial (N ¼
8,680) is now moving forward with NAC to help answer a
question concerning the preventive effectiveness of this agent,
which has been both used and questioned for decades (18).
In conclusion, as CI-AKI rates are decreasing and
guidelines now suggest formal approaches for risk stratiﬁ-
cation and detection, we remain in need of bona ﬁde
preventive approaches until less toxic iodinated contrast can
be commercialized. The penultimate question remains: if we
prevent or lessen CI-AKI as determined by serum creati-
nine, will we reduce the rates of clinical outcomes including
end-stage renal disease, and mortality and more secondary
events including the development of heart failure, recurrent
acute coronary syndromes, and stroke? Only large-scale trials
with effective therapies and adequate follow-up for these
outcomes will answer this pivotal question.
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